Filter Content:

Infographics

14 Jun 2024

Erratum: Ozanimod Long-Term Safety and Efficacy

In the infographic published under AMJ Neurology, on 30th May 2024, the graphs depicting safety over time titled ‘Malignancy TEAEs’…

30 May 2024

Ozanimod Long-Term Safety and Efficacy

S1P receptor 1 and 5 modulator for relapsing forms of MS in adults, including clinically isolated syndrome, relapsing-remitting disease…

12 Apr 2024

JAK Inhibitors for Alopecia Areata

Exploring the promise of Janus kinase inhibitors (JAKi) in treating alopecia areata (AA), this infographic outlines the mechanism of…

22 Oct 2025

Standard of Care: Real-world Needs and Real-world Stories in Parkinson’s Disease

The Bial symposium ‘Standard of care: Real-world needs and real-world stories in Parkinson’s disease’ at the 11th Annual Congress of the…

12 Sep 2025

The POSITIVE Phase IV Study: Interim 52-Week Results on Patient Well-Being With Tildrakizumab

Psoriatic disease extends beyond the skin, imposing a significant psychosocial burden, often leading to embarrassment, social withdrawal…

3 Sep 2025

Update to European Treatment Guideline for Large B Cell Lymphomas

A 2025 EHA guideline for managing large B-cell lymphoma includes new recommendations for CAR T-cell therapy in patients who…

31 Jul 2025

CANYON: The Largest Interventional Trial in Becker

Sevasemten is an investigational agent that is currently not approved for use by any regulatory authority in any territory…

24 Jul 2025

Ranking Treatments for Lenalidomide-Refractory Multiple Myeloma post DRd

Multiple myeloma is the second most common haematological malignancy, with an increasing global incidence…

Loading posts...

« Previous 1 2 3 4 5 … 18 Next »